Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
06 October 2016Next earnings report:
01 April 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:19:38 GMTDividend
Analysts recommendations
Institutional Ownership
RSLS Latest News
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications.
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-58 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on September 23, 2024.
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call on May 15, 2024 at 4:30 PM ET featuring Michael Miller, Paul Hickey, and Thomas Stankovich. Thank you for joining the call. Now I will hand it over to Michael Miller from Rx Communications.
ReShape Lifesciences Inc. (Nasdaq: RSLS), a leading company specializing in weight loss and metabolic health solutions, will release its financial results for the first quarter of 2024 and provide a corporate update on Wednesday, May 15, 2024, after the market closes.
ReShape Lifesciences (NASDAQ: RSLS ) stock is rising higher on Wednesday following approval from the Food and Drug Administration (FDA) for a PMA supplement. That a PMA supplement applies to the company's Lap-Band 2.0 FLEX.
ReShape Lifesciences (NASDAQ:RSLS) saw its stock soar, up 41% to 36 cents a share in premarket, after the micro-cap firm's latest obesity treatment, Lap-Band 2.0, was approved by the US Food and Drug Administration (FDA). The FDA provided the company with a PMA supplement approval for the new generation of ReShape's Lap-Band – described as a “minimally invasive alternative to surgical stapling procedures – which features ‘FLEX' technology that the company said acts as a ‘relief valve' allowing larger pieces of food to move more easily through the narrower passage created by the band.
Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023
Reshape Lifesciences (NASDAQ: RSLS ) stock is getting a boost on Wednesday without any clear news from the medical device company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying today.
What type of business is ReShape Lifesciences?
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
What sector is ReShape Lifesciences in?
ReShape Lifesciences is in the Healthcare sector
What industry is ReShape Lifesciences in?
ReShape Lifesciences is in the Medical Devices industry
What country is ReShape Lifesciences from?
ReShape Lifesciences is headquartered in United States
When did ReShape Lifesciences go public?
ReShape Lifesciences initial public offering (IPO) was on 06 October 2016
What is ReShape Lifesciences website?
https://www.reshapelifesciences.com
Is ReShape Lifesciences in the S&P 500?
No, ReShape Lifesciences is not included in the S&P 500 index
Is ReShape Lifesciences in the NASDAQ 100?
No, ReShape Lifesciences is not included in the NASDAQ 100 index
Is ReShape Lifesciences in the Dow Jones?
No, ReShape Lifesciences is not included in the Dow Jones index
When was ReShape Lifesciences the previous earnings report?
No data
When does ReShape Lifesciences earnings report?
The next expected earnings date for ReShape Lifesciences is 01 April 2025